Last reviewed · How we verify

NCT03689361: MARIE

Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase.

Completed Phase 4 Last updated 3 February 2021
What this trial tests

Phase 4 trial testing MRI in Migraine Aura in 60 participants. Completed in 11 December 2020.

Timeline
22 December 2018
Primary endpoint
11 October 2020
11 December 2020

Quick facts

Lead sponsorUniversity Hospital, Toulouse
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingdouble
Primary purposediagnostic
Enrollment60
Start date22 December 2018
Primary completion11 October 2020
Estimated completion11 December 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

Adults 18 to 55, any sex, with Migraine Aura. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

investigators hypothesize that T2 \* vein abnormalities are frequent and are specific to the migraine aura.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

Other recruiting trials for Migraine Aura

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03689361.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing